Navigation Links
TB vaccine developed at McMaster University in Canada
Date:3/19/2009

Hamilton, ON (March 19, 2009) - McMaster University researchers are about to launch Canada's first tuberculosis (TB) vaccine clinical trial with a vaccine totally designed, manufactured and tested within McMaster.

"The exciting thing for McMaster is that this is translational research that has gone from the basic science where the vector has been designed here at McMaster, then manufactured here, with all the pre-clinical studies done at McMaster," said Dr. Fiona Smaill, a professor of medicine and chair of the Department of Pathology and Molecular Medicine.

Development of the vaccine for the landmark trial was led by Zhou Xing, a professor in the Department of Pathology and Molecular Medicine. The vaccine was manufactured in the Robert E. Fitzhenry Vector Laboratory of the Institute of Molecular Medicine and Health on campus, Canada's first university laboratory certified to provide vectors (delivery agents) for use in clinical trials in humans. Most of the pre-clinical testing of the vaccine was undertaken at McMaster.

The phase 1 clinical trial, which has the approval of Health Canada, will begin to recruit 48 healthy volunteers between 18 and 55 years of age in mid-April. Over 12 18 months researchers will evaluate the safety of the new vaccine (currently called AdAg85A vaccine) and assess blood samples from vaccinated healthy human volunteers to determine if the vaccine is generating a desired immune response. The trial will be conducted by a team of infectious disease physicians, vaccine manufacturing specialists and immunologists at McMaster.

The announcement of the new TB vaccine trial coincides with World TB Day on Tuesday, March 24, when health authorities and researchers around the world will be raising awareness about the need for new TB vaccines.

Today, TB ranks second only to HIV among infectious killers worldwide, claiming nearly two million lives annually. The disease is evolving faster than therapies with the emergence in recent years of strains that are resistant to every last one of the antibiotic defences.

The McMaster researchers developed the new TB vaccine using a genetically modified adenovirus a virus responsible for the common cold. After removing a small portion of the gene, they inserted part of the TB gene responsible for immunity. "It is natural ways of making the body use its own immune machinery," said Smaill, a physician and infectious disease specialist.

"Based on all pre-clinical studies carried out on animals, including mice, guinea pigs (who are very prone to TB) and cattle, this vaccine appears to be a very promising candidate vaccine," Xing said.

The vaccine, manufactured to clinical grade standards at McMaster, has passed all the testing required for its use in humans, Smaill said. Along with regulatory approval from Ottawa, the TB vaccine trial has been approved by the research ethics board at McMaster University and Hamilton Health Sciences (HSC).


'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
3. Vaccine Stops Alzheimers Brain Tangles
4. Human Papilloma Virus vaccines may decrease chances of oral cancer
5. U.S. Teens Fall Short on Vaccine Coverage
6. Nasal Anthrax Vaccine Proves Effective in Animal Study
7. Hot ice, measuring depression, perfect invisibility and flu vaccine incentives
8. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... The Woodlands, Texas (PRWEB) , ... August 23, 2017 , ... ... the leading denied claims firms in Texas. Founded by Bill Voss, the firm grew ... over a decade and a half of helping clients get the money they deserve ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... Drs. Steven ... whitening in Cornelius, NC. By taking advantage of this offer, valued at more ... every regular six-month hygiene cleaning from the dentist, patients receive a complimentary professional whitening ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... Therapy continues to prove the safety and efficacy of HBOT in treating and ... across the US, points to research showing the similarities of the wounds to ...
(Date:8/23/2017)... , ... August 23, 2017 , ... The Stevie® Awards have announced the winners of ... , the world’s premier business awards competition. , Nominees in the 2017 IBAs were not ... a points system based on the total number of awards won in the IBAs with ...
(Date:8/23/2017)... (PRWEB) , ... August 23, 2017 , ... ... the healthcare industry, made the 2017 Inc. 5000 with a three-year sales ... the nation’s fastest-growing private companies and comprises the most comprehensive look at America’s ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... PETACH TIKVAH, Israel , Aug. 15, ... leading developer of adult stem cell technologies for neurodegenerative ... June 30, 2017. ... our pivotal Phase 3 trial to investigate NurOwn ® ... and Chief Executive Officer of BrainStorm. "We have agreements ...
(Date:8/8/2017)...   Second-quarter 2017 revenues of ... share from continuing operations ... to $110 million Second-quarter ... million Second-quarter 2017 adjusted ... 8 percent to $0.93 ...
(Date:8/7/2017)... Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, announced ... comparisons, unless otherwise noted, are to the quarter ended June ... Quarter 2017 Highlights include: Revenue of ... Total prescriptions dispensed of 220,000, compared to ... Gross profit per prescription dispensed of ...
Breaking Medicine Technology: